Skip to main content

Table 3 Adverse events in the treated population

From: A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations – results of a prematurely terminated study

  Vancomycin (n = 7) Daptomycin (n = 7) All (n = 14)
Serious adverse eventsa 4 3 7
Adverse events    
Cardiac arrhythmia 2 1 3
General cardiacb 2 1 3
Constitutional symptomsc 0 2 2
Dermatologicd 3 0 3
Adrenal insufficiency 0 1 1
Eosinophilia 0 1 1
Fall 1 1 2
Nausea and vomiting 0 1 1
Anemia 1 1 2
Infectione 3 4 7
Neurologicalf 2 1 3
Pain 2 1 3
Hematuria 0 1 1
  1. Data are number of cases
  2. aIn the vancomycin arm this included intracranial hemorrhage, catheter-related infection, acute coronary syndrome and vascular access complication. In the daptomycin arm this included catheter-related infection and hypotension
  3. bIncluding adverse events termed “acute coronary event”, “hypotension”, and “pulmonary edema”
  4. cIncluding events termed “somnolence” and “fever”
  5. dIncluding events termed “rash-maculopapular” and “pruritus”
  6. eIncluding events termed “catheter-related infection” and “urinary tract infection”
  7. fIncluding events termed “seizure”, “intracranial hemorrhage”, and “dizziness”